In this episode of BioTalk, Locust Walk’s Vice President, Josh Hamermesh, spoke to Roger Longman, CEO of Real Endpoints, about the pricing and reimbursement issues that are affecting the biopharmaceutical industry, with a particular focus on the impact on deal making. Highlights of the conversation include:

• Major shifts in the pharmaceutical industry in recent decades
• Why pharmaceutical pricing and reimbursement became such a ‘hot button’ topic
• Trends towards value-based pricing and ‘pay for performance’ approached
• Recent high profile product launches and pricing decisions
• Implications of pricing / reimbursement environment on life science deal making and business development